Streetbeat News

TVGN

Tevogen Bio Holdings Inc.

Industry

Biotechnology

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

Open

1.12

Mkt cap

205M

Volume

202K

High

1.18

P/E Ratio

3.34

52-wk high

6.25

Low

1.12

Div yield

N/A

52-wk low

0.26

Tevogen Bio has filed a patent for a new T cell vaccine, utilizing its proprietary Tevogen.AI-powered PredicTcell technology to stimulate a T cell response. This development marks a significant step in the company's immunotherapy efforts.

Portfolio Pulse from

March 10, 2025 | 5:00 pm

Tevogen Bio (Nasdaq: TVGN) will receive an additional $8 million in non-dilutive grant funding from KRHP LLC, following a successful evaluation of its progress, particularly in its AI efforts. This funding is expected before the end of the current fiscal quarter.

Portfolio Pulse from

March 03, 2025 | 6:00 pm

Tevogen Bio's CEO, Dr. Ryan Saadi, has been named to the 2025 NJBIZ Power 100, highlighting his leadership in T Cell therapy innovation. This recognition underscores Tevogen Bio's influence in New Jersey's business landscape.

Portfolio Pulse from

February 28, 2025 | 6:30 pm

Tevogen Bio's CEO, Ryan Saadi, reaffirms the company's commitment to preserving equity for shareholders, focusing on efficiency, asset ownership, and a path to revenue.

Portfolio Pulse from

February 14, 2025 | 11:45 pm

Tevogen Bio, a clinical-stage specialty immunotherapy biotech company, shared its 2024 financing activities on the first anniversary of its Nasdaq listing. The company highlighted its operational efficiency.

Portfolio Pulse from

February 14, 2025 | 6:30 pm

Tevogen Bio's CEO, Dr. Saadi, discusses the potential negative impact of short selling on the nation's health and prosperity, while reaffirming the company's commitment to its shareholders.

Portfolio Pulse from

February 14, 2025 | 5:00 pm

Tevogen Bio's CEO congratulates Robert F. Kennedy Jr. on his confirmation as Secretary of Health and Human Services, emphasizing a shared commitment to innovation and affordability in healthcare.

Portfolio Pulse from

February 13, 2025 | 9:45 pm

Tevogen Bio, a clinical-stage specialty immunotherapy biotech company, is addressing biopharma industry challenges with a cost-efficient innovation model. This positions the company as a potential leader in the shift towards value-driven healthcare amidst increasing competition and regulatory changes.

Portfolio Pulse from

February 10, 2025 | 10:45 pm

Tevogen Bio (Nasdaq: TVGN) has entered into an agreement to receive up to $10 million in non-dilutive grant funding from KRHP LLC. The initial contribution is $2 million, with a potential additional $8 million contingent on future reviews. This funding will support Tevogen Bio's development of T cell therapeutics for cancer and viral infections.

Portfolio Pulse from

January 28, 2025 | 9:00 pm

Tevogen Bio's CEO, Dr. Ryan Saadi, congratulates Lynne Patton on her new role as Deputy Assistant to the President and Director of Minority Outreach. Tevogen Bio is a clinical-stage specialty immunotherapy biotech company.

Portfolio Pulse from

January 27, 2025 | 7:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.